Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma
Copyright 2023, International Institute of Anticancer Research..
BACKGROUND/AIM: Several prognostic risk factors have been recognized when using cisplatin-based conventional chemotherapy for the treatment of advanced urothelial carcinoma (UC); these include performance status (PS), liver metastasis, hemoglobin (Hb) levels, time from prior chemotherapy (TFPC), and other systemic inflammation scores including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). However, the benefit of these indicators for predicting outcome of immune checkpoint inhibitors is not fully understood. Here, we investigated the predictive value of the indicators in patients who received pembrolizumab for the treatment of advanced UC.
PATIENTS AND METHODS: Seventy-five patients who received pembrolizumab treatment for advanced UC were included. The Karnofsky PS, liver metastasis, hemoglobin levels, TFPC, NLR, and PLR were analyzed, and their relationship with overall survival (OS) was determined.
RESULTS: All factors were highlighted as significant prognostic indicators for OS in the univariate proportional regression analysis (p<0.05 for each). Multivariate analysis revealed that Karnofsky PS and liver metastasis were independent prognostic indicators for OS (p<0.01) but were applicable only for a small number of patients. Notably, the combined analysis with low Hb levels and high PLR was significantly associated with OS in patients who could gain less benefit from pembrolizumab at a median of 6.6 [95% confidence interval (CI)=4.2-9.0] versus 15.1 (95% CI=12.4-17.8) months (p=0.002).
CONCLUSION: The combination of Hb levels and PLR may be a broadly applicable indicator for the outcome of pembrolizumab as second-line chemotherapy in patients with advanced UC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Cancer diagnosis & prognosis - 3(2023), 2 vom: 15. März, Seite 230-235 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kurashina, Ryo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hemoglobin level |
|---|
| Anmerkungen: |
Date Revised 07.03.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21873/cdp.10206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35381184X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35381184X | ||
| 003 | DE-627 | ||
| 005 | 20231226060855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/cdp.10206 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM35381184X | ||
| 035 | |a (NLM)36875313 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kurashina, Ryo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright 2023, International Institute of Anticancer Research. | ||
| 520 | |a BACKGROUND/AIM: Several prognostic risk factors have been recognized when using cisplatin-based conventional chemotherapy for the treatment of advanced urothelial carcinoma (UC); these include performance status (PS), liver metastasis, hemoglobin (Hb) levels, time from prior chemotherapy (TFPC), and other systemic inflammation scores including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). However, the benefit of these indicators for predicting outcome of immune checkpoint inhibitors is not fully understood. Here, we investigated the predictive value of the indicators in patients who received pembrolizumab for the treatment of advanced UC | ||
| 520 | |a PATIENTS AND METHODS: Seventy-five patients who received pembrolizumab treatment for advanced UC were included. The Karnofsky PS, liver metastasis, hemoglobin levels, TFPC, NLR, and PLR were analyzed, and their relationship with overall survival (OS) was determined | ||
| 520 | |a RESULTS: All factors were highlighted as significant prognostic indicators for OS in the univariate proportional regression analysis (p<0.05 for each). Multivariate analysis revealed that Karnofsky PS and liver metastasis were independent prognostic indicators for OS (p<0.01) but were applicable only for a small number of patients. Notably, the combined analysis with low Hb levels and high PLR was significantly associated with OS in patients who could gain less benefit from pembrolizumab at a median of 6.6 [95% confidence interval (CI)=4.2-9.0] versus 15.1 (95% CI=12.4-17.8) months (p=0.002) | ||
| 520 | |a CONCLUSION: The combination of Hb levels and PLR may be a broadly applicable indicator for the outcome of pembrolizumab as second-line chemotherapy in patients with advanced UC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PLR | |
| 650 | 4 | |a Urothelial carcinoma | |
| 650 | 4 | |a hemoglobin level | |
| 650 | 4 | |a pembrolizumab | |
| 700 | 1 | |a Ando, Kiyohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Masaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Riko |e verfasserin |4 aut | |
| 700 | 1 | |a Mitani, Kouki |e verfasserin |4 aut | |
| 700 | 1 | |a Takenobu, Hisanori |e verfasserin |4 aut | |
| 700 | 1 | |a Haruta, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Onuki, Ritsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuoka, Yoh |e verfasserin |4 aut | |
| 700 | 1 | |a Kamijo, Takehiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kageyama, Yukio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer diagnosis & prognosis |d 2021 |g 3(2023), 2 vom: 15. März, Seite 230-235 |w (DE-627)NLM33928790X |x 2732-7787 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2023 |g number:2 |g day:15 |g month:03 |g pages:230-235 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/cdp.10206 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2023 |e 2 |b 15 |c 03 |h 230-235 | ||